Alector (NASDAQ:ALEC) Posts Earnings Results

Alector (NASDAQ:ALEC - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.59, Zacks reports. The business had revenue of $54.24 million during the quarter, compared to analysts' expectations of $20.41 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. Alector updated its FY 2025 guidance to EPS.

Alector Stock Performance

Shares of NASDAQ ALEC traded down $0.02 during mid-day trading on Friday, hitting $1.64. The stock had a trading volume of 2,412,836 shares, compared to its average volume of 657,637. The business has a 50 day moving average price of $1.77 and a two-hundred day moving average price of $3.50. Alector has a 1 year low of $1.55 and a 1 year high of $7.57. The firm has a market cap of $162.50 million, a P/E ratio of -0.96 and a beta of 0.61.

Insider Activity at Alector

In other news, CEO Arnon Rosenthal sold 52,172 shares of the firm's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $2.52, for a total value of $131,473.44. Following the transaction, the chief executive officer now owns 2,507,074 shares of the company's stock, valued at $6,317,826.48. This trade represents a 2.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sara Kenkare-Mitra sold 26,500 shares of Alector stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $66,780.00. Following the sale, the insider now directly owns 565,215 shares in the company, valued at $1,424,341.80. This trade represents a 4.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 95,161 shares of company stock valued at $239,806 in the last three months. Company insiders own 9.10% of the company's stock.

Analysts Set New Price Targets

ALEC has been the topic of several recent analyst reports. BTIG Research lowered their price target on Alector from $16.00 to $5.00 and set a "buy" rating on the stock in a research report on Tuesday, November 26th. Stifel Nicolaus cut Alector from a "buy" rating to a "hold" rating and set a $4.00 price target for the company. in a report on Monday, December 16th. Cantor Fitzgerald reissued an "overweight" rating on shares of Alector in a report on Tuesday, November 26th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Alector in a research report on Thursday. Finally, Mizuho lowered Alector from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $9.00 to $2.50 in a research report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $3.75.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.